Grant Award Details

Combating Ovarian Cancer Using Stem Cell-Engineered Off-The-Shelf CAR-iNKT Cells
Grant Type: 
Grant Number: 
DISC2-13505
Project Objective: 
  • To develop a cell therapy candidate, HSC-engineered allogeneic mesothelin-targeting CAR-iNKT (AlloMCAR-iNKT) cells, for treating ovarian cancer.
Investigator: 
Name: 
Institution: 
Type: 
PI
Disease Focus: 
Cancer
Ovarian Cancer
Solid Tumors
Human Stem Cell Use: 
Adult Stem Cell
Award Value: 
$1,404,000
Status: 
Active

Grant Application Details

Application Title: 
  • Combating Ovarian Cancer Using Stem Cell-Engineered Off-The-Shelf CAR-iNKT Cells
Public Abstract: 

Research Objective

HSC-engineered allogeneic mesothelin-targeting CAR-iNKT (AlloMCAR-iNKT) cells

Impact

treatment of ovarian cancer

Major Proposed Activities

  • Milestone 1. Production of the AlloMCAR-iNKT cells
  • Milestone 2. Characterization of the AlloMCAR-iNKT cells
  • Milestone 3. Delivery of the new therapeutic candidate
Statement of Benefit to California: 

Ovarian cancer (OC) is the leading cause of death among women with gynecological malignancies. In the USA, California is the state with the highest incidences and deaths of ovarian cancer. In 2021, it is estimated that 2,550 women will be diagnosed with OC and 1,640 women will die from this disease at California. Therefore, novel therapies are urgently needed. The proposed project can potentially lead to a novel off-the-shelf cell therapy for ovarian cancer and save lives

  • Share
PrintPDF version